These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 15934127

  • 1. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.
    Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, Rahman MU.
    Arthritis Rheum; 2005 Jun 15; 53(3):337-42. PubMed ID: 15934127
    [Abstract] [Full Text] [Related]

  • 2. Open trial of methotrexate as treatment for autoimmune hearing loss.
    Matteson EL, Fabry DA, Facer GW, Beatty CW, Driscoll CL, Strome SE, McDonald TJ.
    Arthritis Rheum; 2001 Apr 15; 45(2):146-50. PubMed ID: 11324778
    [Abstract] [Full Text] [Related]

  • 3. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.
    Rahman MU, Poe DS, Choi HK.
    Otol Neurotol; 2001 Sep 15; 22(5):619-24. PubMed ID: 11568668
    [Abstract] [Full Text] [Related]

  • 4. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
    Haynes DS, O'Malley M, Cohen S, Watford K, Labadie RF.
    Laryngoscope; 2007 Jan 15; 117(1):3-15. PubMed ID: 17202923
    [Abstract] [Full Text] [Related]

  • 5. Methotrexate in the management of immune mediated cochleovesitibular disorders: clinical experience with 53 patients.
    Salley LH, Grimm M, Sismanis A, Spencer RF, Wise CM.
    J Rheumatol; 2001 May 15; 28(5):1037-40. PubMed ID: 11361185
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.
    Rheumatology (Oxford); 2005 Mar 15; 44(3):342-8. PubMed ID: 15561737
    [Abstract] [Full Text] [Related]

  • 7. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
    Mazzotta A, Esposito M, Schipani C, Chimenti S.
    J Dermatolog Treat; 2009 Mar 15; 20(6):354-8. PubMed ID: 19954392
    [Abstract] [Full Text] [Related]

  • 8. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease.
    Wu IC, Minor LB.
    Laryngoscope; 2003 May 15; 113(5):815-20. PubMed ID: 12792316
    [Abstract] [Full Text] [Related]

  • 9. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.
    Henrickson M, Reiff A.
    J Rheumatol; 2004 Oct 15; 31(10):2055-61. PubMed ID: 15468375
    [Abstract] [Full Text] [Related]

  • 10. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study.
    Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C.
    Arthritis Rheum; 2007 Dec 15; 57(8):1514-9. PubMed ID: 18050171
    [Abstract] [Full Text] [Related]

  • 11. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun 15; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    J Rheumatol; 2004 Mar 15; 31(3):531-8. PubMed ID: 14994401
    [Abstract] [Full Text] [Related]

  • 14. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study.
    Cohen S, Shoup A, Weisman MH, Harris J.
    Otol Neurotol; 2005 Sep 15; 26(5):903-7. PubMed ID: 16151336
    [Abstract] [Full Text] [Related]

  • 15. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun 15; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 16. Etanercept, a tumour necrosis factor alpha receptor antagonist, and methotrexate in acute sensorineural hearing loss.
    Street I, Jobanputra P, Proops DW.
    J Laryngol Otol; 2006 Dec 15; 120(12):1064-6. PubMed ID: 17040588
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr 15; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 18. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, Freundlich B, Chang DJ, Etanercept Study 400 Investigators.
    Ann Rheum Dis; 2008 Feb 15; 67(2):182-8. PubMed ID: 17728331
    [Abstract] [Full Text] [Related]

  • 19. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.
    Van Wijk F, Staecker H, Keithley E, Lefebvre PP.
    Audiol Neurootol; 2006 Feb 15; 11(6):357-65. PubMed ID: 16988499
    [Abstract] [Full Text] [Related]

  • 20. Low-dose oral methotrexate management of patients with bilateral Ménière's disease.
    Kilpatrick JK, Sismanis A, Spencer RF, Wise CM.
    Ear Nose Throat J; 2000 Feb 15; 79(2):82-3, 86-8, 91-2. PubMed ID: 10697931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.